📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,076
All-time analysed
43,619
Positive
6,746
Negative
92,864
Neutral
8,779
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
848 announcements match the current filters (relevance ≥ 5).
Birla Corp Recommends ₹12.50 Dividend and Approves FY26 Audited Financial Results
Birla Corporation's Board has approved the audited financial results for the fiscal year ending March 31, 2026. A significant highlight for shareholders is the recommendation of a ₹12.50 per share dividend, representing a 125% payout on ordinary shares. The company also ensured leadership stability by extending the term of its Company Secretary and Legal Head, Manoj Kumar Mehta, for four additional years through October 2030. These decisions reflect a focus on consistent shareholder returns and corporate governance continuity.
Key Highlights
Recommended a final dividend of ₹12.50 per share (125%) for the financial year 2025-26.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Extended the service term of Manoj Kumar Mehta, CS & Legal Head, for 4 years from November 2026 to October 2030.
Dividend payment is scheduled within 30 days of shareholder approval at the upcoming AGM.
👀 What to Watch
Investors should view the dividend recommendation as a positive sign of cash flow health. It is advisable to review the full financial statements to assess volume growth and margin performance in the cement segment.
Biocon Proposes CEO Appointment and Revision in Executive Chairperson's Remuneration
Biocon Limited has initiated a postal ballot to seek shareholder approval for several key leadership and structural changes. The company proposes appointing Mr. Shreehas Pradeep Tambe as CEO & MD for a five-year term starting April 1, 2026. Additionally, it seeks to revise Executive Chairperson Kiran Mazumdar-Shaw's annual remuneration to a cap of ₹21 crore from Biocon and ₹25 crore on a consolidated basis with Syngene. The ballot also includes a proposal for a preferential issue of equity shares for consideration other than cash, indicating potential inorganic growth or asset acquisition.
Key Highlights
Appointment of Shreehas Pradeep Tambe as CEO & MD for a 5-year term effective April 1, 2026
Revision of Kiran Mazumdar-Shaw's remuneration cap to ₹21 crore per annum from Biocon
Consolidated remuneration cap for Ms. Shaw (including Syngene) set at ₹25 crore per annum
Proposal for issuance of equity shares on a preferential basis for consideration other than cash
Appointment or re-appointment of 7 Independent and Non-Executive Directors to the Board
👀 What to Watch
Investors should monitor the specific details regarding the preferential issue for non-cash consideration as it may signal a strategic acquisition. The leadership transition to Mr. Tambe is a significant long-term development for the company's execution strategy.
SBIN Declares ₹17.35 Dividend per Share; Sets May 16 as Record Date
State Bank of India (SBIN) has declared a dividend of ₹17.35 per equity share for the financial year ended March 31, 2026. This represents a significant payout of 1735% on the face value of ₹1 per share. The bank has fixed May 16, 2026, as the record date to determine shareholder eligibility for this payout. The dividend is scheduled to be paid to eligible shareholders on June 4, 2026.
Key Highlights
Dividend declared at ₹17.35 per equity share of face value ₹1 (1735%)
Record date for determining eligibility is fixed as May 16, 2026
Dividend payment date is scheduled for June 4, 2026
Book closure period set from May 17, 2026, to May 19, 2026
Announcement follows the Central Board meeting held on May 8, 2026
👀 What to Watch
Investors seeking to receive the dividend must ensure they hold SBIN shares in their demat account before the ex-dividend date. The ₹17.35 payout offers a healthy yield for long-term shareholders of India's largest public sector bank.
SBI Declares Final Dividend of ₹17.35 per Share for FY 2025-26
State Bank of India (SBIN) has announced a final dividend of ₹17.35 per equity share for the financial year ended March 31, 2026. This represents a substantial payout of 1735% on the face value of ₹1 per share. The bank has established May 16, 2026, as the record date to identify eligible shareholders for this payout. The dividend is scheduled to be paid to shareholders on June 4, 2026.
Key Highlights
Final dividend of ₹17.35 per equity share declared for FY26
Dividend payout represents 1735% of the ₹1 face value per share
Record date for dividend eligibility set for May 16, 2026
Dividend payment date fixed for June 4, 2026
Register of shareholders closed from May 17 to May 19, 2026
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the record date of May 16, 2026. The healthy payout reflects the bank's strong capital position and commitment to returning value to shareholders.
SBIN Q4FY26: Annual Net Profit Hits ₹80,032 Cr; Asset Quality Improves to 1.49% GNPA
State Bank of India (SBIN) reported a strong FY26 with a full-year net profit of ₹80,032 crores, marking a 12.88% YoY growth. For Q4FY26, net profit stood at ₹19,684 crores, up 5.58% YoY, though it saw a 6.39% sequential decline. The bank demonstrated robust credit growth of 16.87% YoY, led by SME and Agri segments, while maintaining exceptional asset quality with Net NPA at a low of 0.39%. However, Domestic Net Interest Margins (NIM) faced pressure, contracting to 3.03% for FY26 compared to 3.21% in FY25.
Key Highlights
Full-year FY26 Net Profit grew 12.88% YoY to ₹80,032 crores with a healthy ROE of 18.57%.
Gross NPA ratio improved to 1.49% (down 33 bps YoY) and Net NPA ratio stood at 0.39%.
Whole Bank Advances grew 16.87% YoY to ₹49.3 Trillion, while Deposits grew 11.03% to ₹59.8 Trillion.
Domestic NIM for FY26 compressed to 3.03% from 3.21% YoY; Q4FY26 Domestic NIM was 2.93%.
Capital Adequacy Ratio (CRAR) improved to 15.40% with CET-1 at 12.29%.
👀 What to Watch
Investors should view the continued improvement in asset quality and strong loan book growth as key positives. While NIM compression is a sector-wide trend, SBIN's scale and improving capital ratios make it a robust long-term play in the banking sector.
SBI Reports Record Annual Net Profit of ₹80,032 Cr in FY26; GNPA at Two-Decadal Low of 1.49%
State Bank of India (SBI) delivered its highest-ever annual net profit of ₹80,032 crores for FY26, marking a 12.88% YoY growth. The bank's loan book expanded robustly by 16.87% to ₹49.3 lakh crore, driven by strong growth in SME (21%) and Agri (19.7%) segments. Asset quality reached a multi-decade high with GNPA and NNPA ratios improving to 1.49% and 0.39% respectively. While Net Interest Margins (NIM) saw a slight compression of 17-18 bps, the bank maintained a healthy ROE of 18.57% and strengthened its capital adequacy to 15.40%.
Key Highlights
Highest ever annual Net Profit of ₹80,032 crores, growing 12.88% YoY with ROE at 18.57%.
Gross NPA ratio hit a two-decadal low of 1.49% and Net NPA at 0.39% with credit cost at 0.37%.
Total advances grew 16.87% YoY to ₹49.3 lakh crore, while deposits rose 11.03% to ₹59.8 lakh crore.
Capital Adequacy Ratio (CAR) improved by 115 bps YoY to reach 15.40%.
Digital leadership continues with YONO registered users crossing 10.02 crore and 66% of savings accounts opened digitally.
👀 What to Watch
Investors should maintain a positive outlook as SBI demonstrates best-in-class asset quality and robust credit growth across all segments. The minor NIM compression is offset by operating efficiencies and lower credit costs, making it a preferred pick in the banking sector.
SBI FY26 Net Profit Rises 13% to ₹80,032 Cr; Declares ₹17.35 Dividend
State Bank of India (SBI) reported a robust performance for the financial year ended March 31, 2026, with standalone net profit increasing by 12.8% to ₹80,032.01 crore. Asset quality showed significant improvement, with Gross NPA declining to 1.49% from 1.82% and Net NPA dropping to 0.39%. The bank strengthened its capital position, reporting a Capital Adequacy Ratio of 15.40% compared to 14.25% in the previous year. A dividend of ₹17.35 per share was declared, rewarding shareholders following a year of strong profitability and improved Return on Assets (ROA) of 1.12%.
Key Highlights
Standalone Net Profit for FY26 grew to ₹80,032.01 crore versus ₹70,900.63 crore in FY25.
Gross NPA ratio improved significantly to 1.49% from 1.82% YoY, while Net NPA stood at 0.39%.
Declared a dividend of ₹17.35 per equity share (1735%) for the financial year 2025-26.
Capital Adequacy Ratio (Basel III) increased to 15.40% from 14.25% in the previous year.
Consolidated Net Profit for the full year reached ₹83,298.78 crore, up from ₹77,561.34 crore.
👀 What to Watch
Investors should view these results positively as SBI continues to demonstrate superior asset quality and strengthening capital buffers. The stock remains a core portfolio holding for long-term exposure to the Indian banking sector.
Biocon Q4 FY26: Adjusted EBITDA up 29% YoY to ₹1,073 Cr; Biosimilars Drive Growth
Biocon reported a steady Q4 FY26 with consolidated revenue from operations reaching ₹4,517 crore, representing a 10% adjusted YoY growth. The Biosimilars segment remains the primary growth engine, contributing ₹2,756 crore in Q4 with a healthy 26% EBITDA margin. The company has successfully completed the integration of Biocon Biologics and is transitioning from a heavy investment phase to an execution phase focused on margin expansion and deleveraging. While the Generics segment saw a margin improvement to 8%, the CRDMO (Syngene) segment showed modest growth of 2% YoY.
Key Highlights
Q4 FY26 consolidated revenue grew 10% YoY (adjusted for one-time sales) to ₹4,517 crore.
Adjusted EBITDA for Q4 rose 29% YoY to ₹1,073 crore, with margins improving to 23%.
Biosimilars segment revenue grew 12% YoY to ₹2,756 crore, supported by strong performance in North America.
Generics segment EBITDA margin improved 300 bps QoQ to 8%, driven by gLiraglutide launches in Europe.
Full-year FY26 revenue reached ₹16,927 crore with a 25% adjusted growth in EBITDA.
👀 What to Watch
Investors should monitor the ramp-up of recent biosimilar launches and the utilization of new generic facilities to confirm margin expansion. The completion of the Biocon Biologics integration and the shift toward deleveraging makes the company a strong long-term play on global biosimilars.
Biocon Declares Re 0.50 Dividend; To Acquire Remaining 2% Stake in Biocon Biologics for Rs 330 Cr
Biocon's board has recommended a final dividend of Re. 0.50 per share (10%) for FY26, setting July 03, 2026, as the record date. A major strategic move involves acquiring the remaining ~2% stake in its subsidiary, Biocon Biologics, through a preferential issue of 87.92 lakh shares at Rs 376.16 per share, totaling approximately Rs 330.73 crore. The company is also undergoing a significant board and management overhaul to integrate Biocon and Biocon Biologics into a unified global entity. Additionally, S.R. Batliboi & Associates has been appointed as the new statutory auditor for a five-year term.
Key Highlights
Recommended final dividend of Re. 0.50 per equity share (10% of face value) for FY26.
Fixed July 03, 2026, as the record date for dividend entitlement with payment by August 31, 2026.
Approved acquisition of ~2% stake in Biocon Biologics via preferential issue of 87,92,317 shares at Rs 376.16 per share.
Total consideration for the Biocon Biologics stake acquisition is approximately Rs 330.73 crore.
Major board restructuring with the appointment of five new Independent Directors to facilitate subsidiary integration.
👀 What to Watch
Investors should track the July 03 record date for dividend eligibility and view the consolidation of Biocon Biologics as a positive step toward a simplified corporate structure. The preferential issue price of Rs 376.16 serves as a key valuation benchmark for the parent company.
Biocon Q4FY26: Adj. Net Profit Jumps 64% to Rs 179 Cr; EBITDA Up 29% to Rs 1,073 Cr
Biocon reported a strong performance for Q4FY26 with adjusted operating revenue growing 10% YoY to Rs 4,517 crore. The company achieved significant margin expansion, with adjusted EBITDA rising 29% to Rs 1,073 crore and adjusted Net Profit increasing 64% to Rs 179 crore. The Biosimilars segment remains the core growth driver, contributing Rs 2,756 crore in Q4 revenue. For the full year FY26, adjusted Net Profit surged 323% to Rs 436 crore, and the board recommended a final dividend of Rs 0.50 per share.
Key Highlights
Q4FY26 adjusted Net Profit grew 64% YoY to Rs 179 crore; FY26 adjusted Net Profit rose 323% to Rs 436 crore.
Consolidated EBITDA margin for FY26 expanded by 200 basis points to 22% on a like-to-like basis.
Biosimilars segment revenue grew 12% YoY in Q4 to Rs 2,756 crore with a healthy 26% EBITDA margin.
Generics segment showed recovery with 13% adjusted revenue growth in Q4 and a 300 bps sequential margin improvement to 8%.
Board recommended a final dividend of Rs 0.50 per share (10% of face value) for FY26.
👀 What to Watch
Investors should view the margin expansion and successful integration of the biosimilars business as a positive sign of operational efficiency. Monitor the scale-up of recent US launches like Denosumab and the performance of the CRDMO (Syngene) segment for long-term value creation.
Biocon to Acquire Remaining 2% of Biocon Biologics for ₹330 Cr; Recommends 10% Dividend
Biocon's board has approved the acquisition of the remaining ~2% stake in its material subsidiary, Biocon Biologics Limited (BBL), for approximately ₹330.73 crore through a preferential issue of shares at ₹376.16 each. The company also recommended a final dividend of ₹0.50 per share (10%) for FY26, with a record date set for July 03, 2026. Significant board restructuring is underway to integrate Biocon and BBL into a unified global biopharmaceutical leader, including the appointment of five new independent directors. Additionally, the board approved the conversion of OCDs and CCDs held by Goldman Sachs and Edelweiss into equity shares of BBL.
Key Highlights
Acquisition of ~2% stake in Biocon Biologics via issuance of 87.92 lakh shares at ₹376.16 per share, totaling ₹330.73 crore.
Recommendation of a 10% final dividend (₹0.50 per share) for the financial year ended March 31, 2026.
Major board overhaul with 5 new Independent Directors and 1 Non-Executive Director to facilitate Biocon-BBL integration.
Conversion of 1,125 OCDs (Goldman Sachs) and 1.06 crore CCDs (Edelweiss) into equity shares of Biocon Biologics.
Appointment of S. R. Batliboi & Associates LLP as new Statutory Auditors for a 5-year term starting August 2026.
👀 What to Watch
Investors should view the consolidation of Biocon Biologics as a positive step toward simplifying the corporate structure and capturing full value from the biologics business. The board strengthening and dividend payout reflect management's confidence in the unified global strategy.
Biocon to Acquire Remaining 2% Stake in Biocon Biologics for Rs 330.73 Cr; Recommends 10% Dividend
Biocon's board has approved the acquisition of the remaining ~2% stake in its subsidiary, Biocon Biologics Limited (BBL), for approximately Rs 330.73 crore through a preferential share issue at Rs 376.16 per share. The company also recommended a final dividend of Re 0.50 per share (10%) for FY26, with a record date of July 03, 2026. A major board restructuring is underway to integrate Biocon and BBL into a unified global entity, including the appointment of five new independent directors. Furthermore, the company approved the conversion of debentures held by Goldman Sachs and Edelweiss into BBL equity shares.
Key Highlights
Acquisition of ~2% BBL stake for Rs 330.73 crore via issuance of 87,92,317 shares at Rs 376.16 each.
Recommended final dividend of Re 0.50 per equity share (10% of face value) for the financial year ended March 31, 2026.
Conversion of 1,125 OCDs and 1.06 crore CCDs into equity shares of Biocon Biologics Limited.
Major board overhaul with 5 new Independent Directors appointed to facilitate Biocon-BBL integration.
Appointment of S. R. Batliboi & Associates LLP as new statutory auditors for a 5-year term starting 2026.
👀 What to Watch
Investors should view the consolidation of Biocon Biologics as a strategic positive that simplifies the corporate structure and aligns interests. Monitor the upcoming shareholder votes on the preferential issue and board appointments.
Biocon Approves 10% Dividend and Rs 330 Cr Stake Hike in Biologics Unit
Biocon's board has recommended a final dividend of Re. 0.50 per share (10%) for FY26, with a record date of July 03, 2026. The company is consolidating its ownership in Biocon Biologics (BBL) by acquiring the remaining ~2% stake for Rs. 330.73 Crores through a preferential issue of 87.92 lakh shares at Rs. 376.16 each. Additionally, a significant board restructuring is underway with the appointment of five new Independent Directors to facilitate the integration of Biocon and BBL into a unified global entity. The board also approved the conversion of OCDs and CCDs held by Goldman Sachs and Edelweiss into BBL equity shares.
Key Highlights
Recommended final dividend of Re. 0.50 per share (10% of face value) for the financial year ended March 31, 2026.
Acquiring remaining ~2% stake in Biocon Biologics for Rs. 330.73 Crores via preferential issue of 87,92,317 shares.
Preferential issue price fixed at Rs. 376.16 per share, including a premium of Rs. 371.16.
Major board overhaul with 5 new Independent Directors and 1 Non-Executive Director to drive BBL integration.
Approved conversion of 1,125 OCDs and 1.06 crore CCDs held by Goldman Sachs and Edelweiss into BBL equity shares.
👀 What to Watch
The consolidation of the Biologics arm and the board overhaul signal a strategic move towards a unified corporate structure, which should improve operational efficiency. Investors should view the dividend and stake consolidation as positive signs of corporate maturity and long-term value alignment.
Biocon to Acquire 2% BBL Stake for ₹330 Cr, Declares Dividend, and Appoints New Auditors
Biocon has announced a final dividend of ₹0.50 per share for FY26 and a major board restructuring to integrate Biocon Biologics (BBL). The company will acquire the remaining ~2% stake in BBL for ₹330.73 crores via a preferential issue of 87.92 lakh shares at ₹376.16 each. S. R. Batliboi & Associates LLP will replace B S R & Co. LLP as statutory auditors for a five-year term. Furthermore, the board approved the conversion of BBL's convertible debentures held by Goldman Sachs and Edelweiss into equity to simplify the capital structure.
Key Highlights
Recommended final dividend of ₹0.50 per share (10%) for FY26 with a record date of July 03, 2026.
Acquisition of ~2% BBL stake for ₹330.73 Crores through issuance of 87,92,317 shares at ₹376.16 per share.
Transition of Statutory Auditors to S. R. Batliboi & Associates LLP for a 5-year term starting from the 48th AGM.
Conversion of 1,125 OCDs and 1.06 crore CCDs held by Goldman Sachs and Edelweiss into BBL equity shares.
Appointment of five new Independent Directors and two Senior Management Personnel to drive global integration.
👀 What to Watch
Investors should view the consolidation of the Biologics business and board strengthening as positive long-term signals for corporate governance and operational synergy. Shareholders should support these measures at the upcoming AGM to facilitate the company's transition into a unified global biopharmaceutical leader.
Biocon Recommends ₹0.50 Dividend; To Acquire Remaining 2% Stake in Biocon Biologics for ₹330.73 Cr
Biocon has announced a final dividend of ₹0.50 per share for FY26, fixing July 03, 2026, as the record date. The company is moving to fully own Biocon Biologics by acquiring the remaining ~2% stake for ₹330.73 crore via a preferential share issue at ₹376.16 per share. Furthermore, the board has approved a major leadership overhaul and the appointment of S. R. Batliboi & Associates as new auditors. These moves aim to create a unified global biopharmaceutical leader by integrating Biocon and its biologics subsidiary.
Key Highlights
Final dividend of ₹0.50 per share (10% of face value) recommended for FY 2025-26.
Preferential issue of 87,92,317 shares at ₹376.16 per share to acquire remaining ~2% stake in Biocon Biologics.
Conversion of 1,125 OCDs and 1,06,86,044 CCDs into equity shares of Biocon Biologics approved.
Appointment of S. R. Batliboi & Associates LLP as Statutory Auditors for a 5-year term starting August 2026.
Record date for dividend set as July 03, 2026, with payment scheduled on or before August 31, 2026.
👀 What to Watch
The consolidation of the biologics business is a strategic positive for long-term value creation and simplified corporate structure. Investors should maintain positions while tracking the impact of the new board composition on global execution.
Biocon Recommends 10% Dividend and to Acquire Remaining 2% Stake in Biocon Biologics for ₹330 Cr
Biocon's board has recommended a final dividend of ₹0.50 per share for FY26 and approved the acquisition of the remaining ~2% stake in its material subsidiary, Biocon Biologics Limited (BBL). The acquisition will be executed via a preferential issue of 87.92 lakh shares at ₹376.16 per share, totaling ₹330.73 Crores. Additionally, the company is undergoing a significant board restructuring to integrate BBL and has appointed S. R. Batliboi & Associates LLP as the new statutory auditors for a 5-year term.
Key Highlights
Recommended a final dividend of 10% (₹0.50 per share) for the financial year ended March 31, 2026.
Acquiring remaining ~2% stake in Biocon Biologics via preferential issue of 87,92,317 shares at ₹376.16 each.
Approved conversion of 1,125 OCDs and 1,06,86,044 CCDs into equity shares of Biocon Biologics.
Major board overhaul with the appointment of 5 new Independent Directors to create a 'Unified Global Biopharmaceutical Leader'.
Appointed S. R. Batliboi & Associates LLP as Statutory Auditors for 5 years, replacing B S R & Co. LLP.
👀 What to Watch
Investors should monitor the integration process of Biocon Biologics, as the consolidation of ownership and board restructuring suggests a move toward a more streamlined global operation. The preferential issue price of ₹376.16 provides a benchmark for the company's internal valuation.
Bigbloc Construction Commences Commercial Production at Umargaon Chemicals Plant
Bigbloc Construction's wholly owned subsidiary, Bigbloc Building Elements Private Limited, has officially started commercial production at its Umargaon facility as of May 7, 2026. This follows the successful completion of trial production which began on April 17, 2026. The new plant focuses on manufacturing construction chemicals, representing a strategic expansion into high-value construction materials. This milestone is expected to enhance the company's product portfolio and drive future revenue growth through diversification.
Key Highlights
Commercial production at Umargaon facility commenced on May 7, 2026
Facility is operated by 100% subsidiary Bigbloc Building Elements Private Limited
Strategic entry into the high-growth construction chemicals segment
Successful transition from trial production which started on April 17, 2026
👀 What to Watch
Investors should view this as a positive growth catalyst and monitor the facility's capacity utilization and its impact on margins in upcoming quarterly reports.
Biocon Denies Succession Rumors; Kiran Mazumdar-Shaw to Continue as Executive Chairperson
Biocon Limited has officially clarified to the stock exchanges that media reports regarding the appointment of Claire Mazumdar as successor are incorrect. The company stated that Kiran Mazumdar-Shaw continues to serve as the Executive Chairperson and is not stepping down from her role. The management emphasized that the company is currently led by a professional team under CEO & Managing Director Shreehas Tambe. This clarification was issued on May 6, 2026, following a query from BSE and NSE regarding speculative news and material price movement.
Key Highlights
Biocon denies reports of Claire Mazumdar being chosen as successor to Kiran Mazumdar-Shaw.
Kiran Mazumdar-Shaw remains the Executive Chairperson with no impending change in management.
Company confirms no material information regarding ownership succession exists under SEBI Regulation 30.
Professional leadership continues under CEO & Managing Director Shreehas Tambe.
Clarification follows stock exchange queries regarding price movement on May 6, 2026.
👀 What to Watch
Investors should disregard speculative media reports and focus on the company's operational performance under the existing professional leadership. The clarification removes immediate uncertainty regarding a leadership transition.
Biocon Denies Succession Rumors; Kiran Mazumdar-Shaw to Continue as Executive Chairperson
Biocon Limited has officially clarified that media reports regarding a leadership succession plan involving Claire Mazumdar are speculative. The company confirmed that Kiran Mazumdar-Shaw will continue in her role as Executive Chairperson and is not stepping down. There are currently no impending changes in executive management or material ownership succession plans that require disclosure under SEBI Regulation 30. The company remains under the professional leadership of CEO and MD Shreehas Tambe.
Key Highlights
Biocon clarifies that Kiran Mazumdar-Shaw is not stepping down as Executive Chairperson.
Company denies any material information regarding ownership succession as of May 06, 2026.
Professional management continues to be led by CEO and Managing Director Shreehas Tambe.
The clarification was issued following surveillance queries from both BSE and NSE regarding price movement.
👀 What to Watch
Investors should disregard speculative reports concerning immediate leadership changes and focus on the company's operational performance. The status quo in top management remains intact, providing continuity for strategic initiatives.
BIL Vyapar Cites CIRP for Non-Applicability of Corporate Governance Reporting for Q4 FY26
BIL Vyapar Limited (formerly Binani Industries Limited) has informed stock exchanges that Regulation 27 regarding Corporate Governance reporting is not applicable for the quarter and year ended March 31, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP), which commenced on January 13, 2026. Ms. Rachana Jhunjhunwala has been appointed as the Resolution Professional to oversee the company's affairs. Under SEBI Regulation 15, companies under CIRP are exempt from specific governance compliance filings.
Key Highlights
Company entered Corporate Insolvency Resolution Process (CIRP) effective January 13, 2026.
Ms. Rachana Jhunjhunwala appointed as the Resolution Professional for the insolvency proceedings.
Exemption from Regulation 27 (Corporate Governance) claimed for the fourth quarter and full year ended March 31, 2026.
The filing follows SEBI (LODR) Regulation 15 which provides relief to companies under insolvency.
👀 What to Watch
Investors should exercise extreme caution as the company is in insolvency proceedings, which often results in significant equity dilution or delisting. Monitor the progress of the resolution plan for any updates on potential recovery value for shareholders.
